Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation

Annals of Neurology

Volumn 69, Issue 4, 2011, Pages 721-734

  Hao, Junwei ^a,b,c   Campagnolo, Denise ^d,e   Liu, Ruolan ^b   Piao, Wenhua ^b   Shi, Samuel ^a,b   Hu, Baoyang ^a   Xiang, Rong ^c   Zhou, Qinghua ^a   Vollmer, Timothy ^f   Van Kaer, Luc ^g   La Cava, Antonio ^h   Shi, Fu Dong ^a,b,i  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^c NANKAI UNIVERSITY   (China)

^d BIOGEN   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NONE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; GRANZYME B; IL 2 MONOCLONAL ANTIBODY IL 2; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 2 ANTIBODY; MONOCLONAL ANTIBODY; PERFORIN; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELL SUBPOPULATION; CENTRAL NERVOUS SYSTEM; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY TEST; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INFLAMMATION; LYMPHOID ORGAN; MALE; MOLECULAR MECHANICS; MOUSE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REMISSION; TARGET ORGAN;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; GRANZYMES; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PERFORIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY;

EID: 79955476247     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22339     Document Type: Article

References (40)

1. Li Z, Lim WK, Mahesh SP, et al. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 2005; 174: 5187-5191. (Pubitemid 40593155)
2. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66: 483-489.
3. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 5941-5946.
4. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9: 381-390.
5. Rose JW, Watt HE, White AT, Carlson NG., Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56: 864-867. (Pubitemid 39578450)
6. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993; 91: 123-132. (Pubitemid 23037263)
7. Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69: 785-789. (Pubitemid 47300936)
8. Cooper MA, Fehniger TA, Caligiuri MA., The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640. (Pubitemid 33043908)
9. Teitelbaum D, Milo R, Arnon R, Sela M., Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A 1992; 89: 137-141.
10. Huang D, Shi FD, Jung S, et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006; 20: 896-905. (Pubitemid 44943947)
11. Mendiratta SK, Martin WD, Hong S, et al. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 1997; 6: 469-477. (Pubitemid 27208202)
12. Smith KA, Favata MF, Oroszlan S., Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics. J Immunol 1983; 131: 1808-1815. (Pubitemid 13006897)
13. Liu R, La Cava A, Bai XF, et al. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 2005; 175: 7898-7904. (Pubitemid 41798350)
14. Cardona AE, Huang D, Sasse ME, Ransohoff RM., Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat Protoc 2006; 1: 1947-1951. (Pubitemid 46773316)
15. Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9: 917-924. (Pubitemid 43980506)
16. Hao J, Liu R, Piao W, et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 2010; 207: 1907-1921.
17. Hayakawa Y, Screpanti V, Yagita H, et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 2004; 172: 123-129. (Pubitemid 38020463)
18. Boyman O, Kovar M, Rubinstein MP, et al. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311: 1924-1927.
19. Bartholomaus I, Kawakami N, Odoardi F, et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009; 462: 94-98.
20. Chung Y, Chang SH, Martinez GJ, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009; 30: 576-587.
21. McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009; 10: 314-324.
22. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 566-573. (Pubitemid 43939170)
23. Zhang B, Yamamura T, Kondo T, et al. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997; 186: 1677-1687. (Pubitemid 27506281)
24. Biber K, Neumann H, Inoue K, Boddeke HW., Neuronal "on" and "off" signals control microglia. Trends Neurosci 2007; 30: 596-602.
25. Hanisch UK, Kettenmann H., Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nature Neurosci 2007; 10: 1387-1394. (Pubitemid 350014685)
26. Pan Y, Lloyd C, Zhou H, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997; 387: 611-617. (Pubitemid 27248766)
27. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-644.
28. Campbell JJ, Qin S, Unutmaz D, et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001; 166: 6477-6482. (Pubitemid 32467184)
29. Jung S, Aliberti J, Graemmel P, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000; 20: 4106-4114. (Pubitemid 30314508)
30. Nimmerjahn A, Kirchhoff F, Helmchen F., Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308: 1314-1318. (Pubitemid 40746128)
31. Shi FD, Van Kaer L., Reciprocal regulation between natural killer cells and autoreactive T cells. Nat Rev Immunol 2006; 6: 751-760. (Pubitemid 44453461)
32. Yu J, Mao HC, Wei M, et al. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 2010; 115: 274-281.
33. Leavenworth JW, Schellack C, Kim HJ, et al. Analysis of the cellular mechanism underlying inhibition of EAE after treatment with anti-NKG2A F(ab)2. Proc Natl Acad Sci U S A 2010; 107: 2562-2567.
34. Kastrukoff LF, Morgan NG, Zecchini D, et al. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. Neurology 1999; 52: 351-359. (Pubitemid 29059064)
35. Kastrukoff LF, Morgan NG, Aziz TM, et al. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon. J Neuroimmunol 1988; 20: 15-23.
36. Martin JF, Perry JS, Jakhete NR, et al. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol 2010; 185: 1311-1320.
37. Courtney LP, Phelps JL, Karavodin LM., An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacology 1994; 28: 223-232. (Pubitemid 24316899)
38. Prlic M, Bevan MJ., Immunology. An antibody paradox, resolved. Science 2006; 311: 1875-1876.
39. Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ., Functional subsets of mouse natural killer cells. Immunol Rev 2006; 214: 47-55. (Pubitemid 44707901)
40. Webster KE, Walters S, Kohler RE, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 2009; 206: 751-760.